News

Researchers discovered that the enzyme HDAC6 can serve as a potential therapeutic target in certain gene mutations related to Charcot-Marie Tooth (CMT) disease, according to new research with mice. The study, “HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease,” appeared in the journal Brain.

A new mouse model that mimics the motor behavior deficits seen in people with Charcot-Marie-Tooth subtype 2O disease (CMT2O) will allow researchers to investigate the molecular mechanisms underlying CMT type 2 disease, a new study says. Researchers at Burnett School of Biomedical Sciences at the University of Central…